Dr. Saro currently serves as Vice President Global Clinical Development at Adaptimmune. Prior to joining Adaptimmune he led the ceralasertib post-PARP inhibitor early clinical development program in solid tumors at AstraZeneca. Prior to that, he worked at Avacta as Chief Medical Officer driving the development strategy of Affimer® programs into the clinic. Before Avacta, Dr. Saro served as Senior Translational Medicine Leader at Roche where he ran three global immunotherapy programs – a targeted cytokine, and two T-cell bispecific antibodies in solid tumors – in collaboration with top academic institutions in the EU and US. Previously, he led global clinical programs at Bristol Myers Squibb including dasatinib, ipilimumab (anti-CTLA4), nivolumab (anti-PD1), anti-PDL1, anti-KIR, anti-LAG3, brivanib, a MEK inhibitor, and elotuzumab. While at Novartis he focused on biomarkers in the preclinical and clinical settings. Dr. Saro earned a medical degree from the University of Oviedo, Spain and a master’s degree in pharmaceutical medicine from Complutense University of Madrid, Spain.